BioCardia takes a new and comprehensive approach to heart failure
We are developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases to improve the lives of patients from unmet medical needs.
Discover us
Financials & Filings
Review our corporate financial reports and SEC filings
Press Releases
Read about our latest company milestones
Clinical Trials
Complete Questionnaire to find out if you or a loved one qulifies for our CardiAMP Heart Failure Study
Product Pipeline
Learn about our product development programs and obtain an at-a-glance view of their current status
News
06 Dec

Fierce Biotech
BioCardia's off-the-shelf cell therapy for heart failure to enter first-in-human study
01 Dec

Empowered Patient Podcast
Optimizing Autologous Cell Therapy to Treat Cardiovascular Disease with Dr. Peter Altman
29 Oct

UW Health
UW Health Treats First Patient in U.S. with Investigational Cell Therapy for Heart Disease
29 Oct

Greenbay CBS
Neenah musician, educator pursues dream after being first in the world to undergo ‘Investigational Cell Therapy’
29 Oct

04 Mar

Henry Ford Health System
Henry Ford Health System Studies Novel Cell Therapy Aimed at Improving Heart Failure Symptoms
08 Feb

15 Sep

03 Aug

Pharmaceutical Technology
BioCardia’s novel CardiAMP stem cell therapy closer to approval in heart failure
press releases
Have questions?
CALL US NOW
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
EMAIL US NOW
: info@biocardia.com
biocardia takes a new and comprehensive
approach to heart failure
By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.